Technical Analysis for AGIO - Agios Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Fell Below 20 DMA | Bearish | 0.05% | |
| Wide Bands | Range Expansion | 0.05% | |
| Wide Bands | Range Expansion | -2.93% | |
| Wide Bands | Range Expansion | -4.09% | |
| 20 DMA Support | Bullish | -4.07% | |
| Pocket Pivot | Bullish Swing Setup | -4.07% | |
| Volume Surge | Other | -4.07% | |
| Earnings Movers | Other | -4.07% | |
| Wide Bands | Range Expansion | -4.07% |
| Alert | Time |
|---|---|
| Possible NR7 | about 6 hours ago |
| 10 DMA Resistance | about 9 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
| Rose Above 10 DMA | about 10 hours ago |
| Up 2% | about 10 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/01/2024
Agios Pharmaceuticals, Inc. Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acid Hydrogen Metabolism Organic Chemistry Glutamate Inborn Errors Of Metabolism Pyruvate Kinase Deficiency
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 49.055 |
| 52 Week Low | 19.795 |
| Average Volume | 857,065 |
| 200-Day Moving Average | 28.31 |
| 50-Day Moving Average | 38.23 |
| 20-Day Moving Average | 45.26 |
| 10-Day Moving Average | 43.62 |
| Average True Range | 1.86 |
| RSI (14) | 54.34 |
| ADX | 26.73 |
| +DI | 28.54 |
| -DI | 23.91 |
| Chandelier Exit (Long, 3 ATRs) | 43.48 |
| Chandelier Exit (Short, 3 ATRs) | 41.71 |
| Upper Bollinger Bands | 49.46 |
| Lower Bollinger Band | 41.06 |
| Percent B (%b) | 0.28 |
| BandWidth | 18.55 |
| MACD Line | 1.45 |
| MACD Signal Line | 2.12 |
| MACD Histogram | -0.6717 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 45.20 | ||||
| Resistance 3 (R3) | 45.31 | 44.81 | 44.90 | ||
| Resistance 2 (R2) | 44.81 | 44.34 | 44.75 | 44.80 | |
| Resistance 1 (R1) | 44.09 | 44.06 | 44.45 | 43.99 | 44.70 |
| Pivot Point | 43.59 | 43.59 | 43.77 | 43.54 | 43.59 |
| Support 1 (S1) | 42.88 | 43.13 | 43.24 | 42.77 | 42.06 |
| Support 2 (S2) | 42.38 | 42.84 | 42.32 | 41.96 | |
| Support 3 (S3) | 41.66 | 42.38 | 41.86 | ||
| Support 4 (S4) | 41.56 |
